



Medicine Supply Notification

MSN/2026/007

Sulfadiazine silver (Flamazine®) 1% cream

Tier 2 – medium impact*

Date of issue: 10/02/2026

Link: [Medicines Supply Tool](#)

Summary

- Sulfadiazine silver (Flamazine®) 1% cream (250g) was discontinued in late December 2025, stock has been exhausted.
- Sulfadiazine silver (Flamazine®) 1% cream (50g) was discontinued in late January 2026, stocks are expected to be exhausted in February 2026.
- Sulfadiazine silver (Flamazine®) 1% cream (20g and 500g) are being discontinued from late June 2026, although stocks are expected to exhaust before this date.
- Alternative products for the treatment of burns and wound care remain available and can support increased demand (see supporting information).
- Unlicensed imported supplies of sulfadiazine silver 1% cream have been sourced (lead times vary) and will be available while stocks in alternative markets permit; availability cannot be guaranteed long-term due to the global discontinuation (see supporting information).

Actions Required

Clinicians should prioritise any remaining supplies for use in patients with burns.

For other indications or where Flamazine® 1% cream is unavailable, clinicians should:

- consider prescribing an alternative product such as Flaminal® gels, UrgoClean® dressing, UrgoTul® dressing, Acticoat® dressings or Prontosan® gels where appropriate, taking into account the ease of use, patient preference and tolerability (see supporting information); or
- consider prescribing unlicensed sulfadiazine silver 1% cream, only where licensed alternatives are not appropriate and where stock is available. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see supporting information); or
- if the above options are not considered appropriate, advice should be sought from burns or tissue viability specialists on management options.

Supporting information

Clinical Information

Flamazine® cream contains silver sulfadiazine, a bacteriostatic and bactericidal agent. It is licensed for the prophylaxis and treatment of infection in burn wounds. It may also be used as an aid to the short-term

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

treatment of infection in leg ulcers and pressure sores, and as an aid to the prophylaxis of infection in skin graft donor sites and extensive abrasions. It is also licensed for the conservative management of finger-tip injuries where pulp, nail loss and/or partial loss of the distal phalanx has occurred. Tubes should be discarded 7 days after opening and the 250g and 500g pots 24 hours after opening. The contents of one container are for the treatment of one person.

Table 1: Examples of antimicrobial wound care products*

Product	Product Classification	Constituents	Uses
Flaminal® Hydro Flaminal® Forte	Medical device	Debriding gel, absorbent alginate and antimicrobial enzyme system	Acute and chronic wounds, or wounds at risk of infection: Flaminal® Hydro for slightly to moderately exuding wounds Flaminal® Forte for wounds with moderate to high amounts of wound exudate
UrgoClean® Ag dressing UrgoTul® Ag/Silver dressing		Hydro-desloughing pad coated with silver-impregnated micro-adherent healing matrix Non-adherent conformable contact layer dressing with silver impregnated micro-adherent healing matrix	Burns Traumatic wounds Surgical wounds Leg, diabetic foot and pressure ulcers
Acticoat® antimicrobial barrier dressing		Silver coated anti-microbial barrier dressing	Partial and full thickness wounds including pressure, venous and diabetic ulcers, surgical wounds, first and second-degree burns, graft and dermal substitutes recipient sites
Prontosan® Wound Gel Prontosan® Wound Gel X (highly viscous)		Antimicrobial polyhexanide (0.1% polyaminopropyl biguanide) and a betaine surfactant	Cleansing, moistening and decontamination of wounds and burns including: Acute, traumatic and postoperative (infected/non-infected) wounds Chronic (infected/non-infected) wounds Burn injuries: I, IIa, IIb and III degree Fistulas and abscesses

*List is not exhaustive; represents suggestions from tissue viability and burns practitioners

[Links to further information](#)

[SmPC: Flamazine® 1% cream](#)

[BNF: Sulfadiazine silver](#)

[Product Information: Flaminal® Hydro/Forte](#)

[Product Information: UrgoClean® Ag](#)

[Product Information: UrgoTul® Ag/Silver](#)

[Product Information: Acticoat® antimicrobial barrier dressing](#)

[Product Information: Prontosan® Wound Gel](#)

[Product Information: Prontosan® Wound Gel X](#)

[Guidance on ordering and prescribing unlicensed imports](#)

The following specialist importers have confirmed they can source unlicensed products (please note there may be other companies that can also source supplies of silver sulfadiazine 1% cream):

- Alium Medical - silver sulfadiazine 1% cream (Silver Sulfadiaz[®])/(Flamazine[®])
- Mawdsley's - silver sulfadiazine 1% cream
- Tanner Pharma Group - silver sulfadiazine 1% cream (Ascend[®])/(Flamazine[®])

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Unlicensed imports do not undergo any central quality assessment or suitability evaluation. Therefore, any import must be locally assessed in line with local unlicensed medicines processes.

Please see the links below for further information:

- [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency (MHRA)
- [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society
- [Prescribing unlicensed medicines](#), General Medical Council (GMC)

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	Dav Manku	Dav.Manku@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	j.eastwood@nhs.net	Daniel Johnson	Daniel.Johnson@nhs.net
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk		
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2026/007.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.